Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Maravai LifeSciences Holdings, Inc. - Class A common stock (NQ:MRVI)

2.135 -0.125 (-5.53%)
Streaming Delayed Price Updated: 2:57 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 570,641
Open 2.200
Bid (Size) 2.130 (49)
Ask (Size) 2.140 (16)
Prev. Close 2.260
Today's Range 2.125 - 2.250
52wk Range 1.665 - 10.03
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology
From TriLink BioTechnologies
Via Business Wire

Performance

YTD
-61.1%
-61.1%
1 Month
+3.6%
+3.6%
3 Month
-11.8%
-11.8%
6 Month
-62.3%
-62.3%
1 Year
-72.9%
-72.9%

More News

Read More
Earnings Scheduled For May 12, 2025
Via Benzinga
Insights Ahead: Maravai LifeSciences's Quarterly Earnings
Via Benzinga
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
Maravai LifeSciencesReleases 2024 Sustainability Report
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
TriLink BioTechnologies® debuts its first mRNA synthesis kit with CleanCap® capping technology; Celebrates launch with kit donations to top academic institutions
From TriLink BioTechnologies
Via Business Wire
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines
From TriLink BioTechnologies
Via Business Wire
These Analysts Slash Their Forecasts On Maravai LifeSciences Following Q1 Results
Via Benzinga
Assessing Maravai LifeSciences: Insights From 5 Financial Analysts
Via Benzinga
Maravai Lifesciences Reports First Quarter 2025 Financial Results
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI
From Pomerantz LLP
Via GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences
From Faruqi & Faruqi, LLP
Via Business Wire
MRVI Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Maravai LifeSciences Holdings, Inc. (MRVI) Investors of Filing Deadline in Class Action Lawsuit
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
MRVI Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Maravai LifeSciences Holdings, Inc. (MRVI) Investors of Filing Deadline in Class Action Lawsuit
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Maravai LifeSciences To Host Earnings Conference Call on Monday, May 12, 2025
From Maravai LifeSciences Holdings LLC
Via GlobeNewswire
MRVI Investors Have the Opportunity to Lead the Maravai LifeSciences Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
From Faruqi & Faruqi LLP
Via GlobeNewswire
Lowey Dannenberg Notifies Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the Firm
From Lowey Dannenberg, P.C.
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holidngs, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against AppLovin, Maravai, e.l.f. Beauty, and Skyworks Solutions and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Maravai LifeSciences Holdings, Inc. (MRVI) Investors: May 5, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via TheNewswire.com
Topics Lawsuit
Exposures Financial Legal
Maravai LifeSciences Holdings, Inc. (MRVI) Investors: May 5, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
MRVI Deadline: Rosen Law Firm Urges Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Maravai LifeSciences
From Faruqi & Faruqi LLP
Via GlobeNewswire

Frequently Asked Questions

Is Maravai LifeSciences Holdings, Inc. - Class A common stock publicly traded?
Yes, Maravai LifeSciences Holdings, Inc. - Class A common stock is publicly traded.
What exchange does Maravai LifeSciences Holdings, Inc. - Class A common stock trade on?
Maravai LifeSciences Holdings, Inc. - Class A common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Maravai LifeSciences Holdings, Inc. - Class A common stock?
The ticker symbol for Maravai LifeSciences Holdings, Inc. - Class A common stock is MRVI on the Nasdaq Stock Market
What is the current price of Maravai LifeSciences Holdings, Inc. - Class A common stock?
The current price of Maravai LifeSciences Holdings, Inc. - Class A common stock is 2.135
When was Maravai LifeSciences Holdings, Inc. - Class A common stock last traded?
The last trade of Maravai LifeSciences Holdings, Inc. - Class A common stock was at 06/13/25 02:57 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.